Yazmín Odia
A5038295657- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- ATP Synthase and ATPases Research
- Brain Metastases and Treatment
- Neuroblastoma Research and Treatments
- Meningioma and schwannoma management
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Cancer Treatment and Pharmacology
- Nanoplatforms for cancer theranostics
- Advanced Radiotherapy Techniques
- Radiation Therapy and Dosimetry
- Cancer Research and Treatments
- Management of metastatic bone disease
- Cancer Immunotherapy and Biomarkers
- CNS Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Pituitary Gland Disorders and Treatments
- Neurofibromatosis and Schwannoma Cases
- Lung Cancer Treatments and Mutations
- Palliative Care and End-of-Life Issues
- Pharmacological Effects and Toxicity Studies
- Brain Tumor Detection and Classification
- Histone Deacetylase Inhibitors Research
Baptist Health South Florida
2016-2025
Florida International University
2019-2025
Baptist Hospital of Miami
2016-2025
Cancer Institute (WIA)
2019-2025
Miami Heart Research Institute
2017-2024
NewYork–Presbyterian Hospital
2015-2021
Columbia University
2013-2021
New York Hospital Queens
2015-2021
Cornell University
2019-2021
Rush University
2021
Abstract Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated two completed multisite studies. following initial radiation prior to recurrence a median overall survival of 21.7 months, whereas those after had 9.3...
Abstract Background Diffuse Midline Glioma (DMG) with the H3K27M mutation is a lethal childhood brain cancer, patients rarely surviving 2 years from diagnosis. Methods We conducted multi-site Phase 1 trial of imipridone ONC201 for children H3K27M-mutant glioma (NCT03416530). Patients enrolled on Arm D (n = 24) underwent serial lumbar puncture cell-free tumor DNA (cf-tDNA) analysis and all arms at University Michigan plasma collection. performed digital droplet polymerase chain reaction...
Histone 3 (H3) K27M-mutant diffuse midline glioma (DMG) has a dismal prognosis with no established effective therapy beyond radiation. This integrated analysis evaluated single-agent ONC201 (dordaviprone), first-in-class imipridone, in recurrent H3 DMG.
The hippo pathway and its downstream mediator yes-associated protein 1 (YAP1) regulate mammalian organ size in part through modulating progenitor cell numbers. YAP1 has also been implicated as an oncogene multiple human cancers. Currently, little is known about the expression of either normal brain tissue or central nervous system neoplasms. We used immunohistochemistry to evaluate nuclear fetal adult brains 264 tumors. was expressed regions harbor neural cells, but there immunoreactivity...
Diffuse intrinsic pontine gliomas (DIPGs) frequently harbor the histone H3 K27M mutation. Gliomas with this mutation commonly overexpress dopamine receptor (DR) D2 and suppress DRD5, leading to enhanced sensitivity DRD2 antagonism. This study reports first clinical experience DRD2/3 antagonist ONC201 as a potential targeted therapy for K27M-mutant DIPG. One pediatric patient (a 10-year-old girl) DIPG was enrolled in an investigator-initiated, IRB-approved compassionate-use began single-agent...
Papillary craniopharyngiomas (PCPs) are characterized by the presence of BRAF V600E mutations, which emerging as a useful guide for diagnosis and treatment decision making. The ongoing multicenter phase 2 Alliance A071601 trial is evaluating efficacy mitogen‐activated protein kinase (MEK) inhibitors patients with PCPs. With continued successful responses, it proposed that (and MEK) be evaluated neoadjuvant
Abstract Background ONC201, a dopamine receptor D2 (DRD2) antagonist and caseinolytic protease P (ClpP) agonist, has induced durable tumor regressions in adults with recurrent H3 K27M-mutant glioma. We report results from the first phase I pediatric clinical trial of ONC201. Methods This open-label, multi-center (NCT03416530) ONC201 for diffuse midline glioma (DMG) or intrinsic pontine (DIPG) employed dose-escalation dose-expansion design. The primary endpoint was recommended II dose (RP2D)....
Abstract Background Despite advances in our understanding of the molecular underpinnings meningioma progression and innovations systemic local treatments, recurrent meningiomas remain a substantial therapeutic challenge. The objective this systematic review meta-analysis is to provide historical baseline, contemporary analysis, propose “rate probable interest” inform future clinical trial design development on behalf RANO group. Methods PubMed, ClinicalTrials.gov, ASCOpubs databases were...
The purpose of this study was to evaluate the activity single-agent bevacizumab in patients with recurrent anaplastic glioma and assess correlative advanced imaging parameters. Patients were treated 10 mg/kg every 2 weeks. Complete patient evaluations repeated 4 Correlative dynamic contrast-enhanced MR 18fluorodeoxyglucose PET studies obtained physiologic changes tumor vasculature at time points including baseline, 96 h after first dose, weeks therapy. Median overall survival 12 months (95%...
Abstract Recent studies suggest that the telomere maintenance mechanism known as alternative lengthening of telomeres ( ALT ) is relatively more common in specific glioma subsets and strongly associated with ATRX mutations. We retrospectively examined 116 high‐grade astrocytomas (32 pediatric glioblastomas, 65 adult 19 anaplastic astrocytomas) status using tissue microarrays to identify associations molecular phenotypic features. Immunohistochemistry was performed antibodies against , DAXX...
We present a patient with BRAF-V600E mutant papillary craniopharyngioma successfully treated combination BRAF (dabrafenib 150 mg twice daily) and MEK (trametinib 2 inhibitors after her unresectable tumor proved refractory to radiation. Serial brain MRIs PET revealed marked reduction gradual neurological improvement permanent panhypopituitarism.
ONC201 is a dopamine receptor D2 (DRD2) antagonist that penetrates the blood-brain barrier. efficacy has been shown in glioblastoma animal models and inversely correlated with DRD5 expression. well tolerated adult recurrent patients dosing every 3 weeks achieved an objective radiographic response patient harboring H3 K27M mutation.In window-of-opportunity arm, 6 subjects initiated prior to re-resection of intratumoral concentrations as primary endpoint. An additional 20 adults received...
// Xing-gang Mao 1,2 , Marianne Hütt -Cabezas 1 Brent A. Orr Melanie Weingart Isabella Taylor Anand K.D. Rajan Yazmin Odia 3,4 Ulf Kahlert 5 Jarek Maciaczyk 6 Guido Nikkhah Charles G. Eberhart Eric H. Raabe 1,7 Department of Pathology, Johns Hopkins University School Medicine, Baltimore, MD 2 Current address: Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China 3 Neurology, 4 Neuro-Oncology Branch, National Cancer Institute, Bethesda, Stereotactic...
Pituitary adenomas are the commonest intracranial tumor, but metastases rare (0.2% yearly incidence) and portend poor prognosis. CAPecitabine TEMozolomide improved outcomes for neuroendocrine tumors. However, no chemotherapy is approved refractory pituitary carcinomas. Next-generation sequencing revealed an actionable mTOR pathway STK11 mutation in a woman with adrenocorticotropic hormone-secreting carcinoma to six resections, radiation TEMozolomide. Given efficacy preclinical pancreatic...
Physicians in most specialties frequently encounter patients with neurologic conditions. For non-neurologists, postgraduate education is variable and often limited, so every medical school9s curriculum must include clinical learning experiences to ensure that all graduating students have the basic knowledge skills required care for common symptoms emergencies. In nearly 20 years elapsed since development of initial American Academy Neurology (AAN)–endorsed core neurology clerkships, many...
Abstract Background This study evaluated the safety and pharmacokinetics (PK) of oral ONC201 administered twice-weekly on consecutive days (D1D2) in pediatric patients with newly diagnosed DIPG and/or recurrent/refractory H3 K27M glioma. Methods phase 1 dose-escalation expansion included K27M-mutant glioma following ≥1 line therapy (NCT03416530). was D1D2 at 3 dose levels (DLs; −1, 1, 2). The actual within DLs dependent weight. Safety assessed all DLs; PK analysis conducted DL2. Patients...
Abstract Background Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant neoplasm of the mucosa. Despite surgical resection combined with radiotherapy and adjuvant chemotherapy, ENB often relapses rapid progression. Current multimodality, nontargeted therapy for relapsed limited clinical benefit. Materials Methods We queried whether comprehensive genomic profiling (CGP) or refractory can uncover alterations (GA) that could identify potential targeted...
Abstract Background Diffuse midline glioma, H3 K27-altered (H3 K27M-altered DMG) are invariably lethal, disproportionately affecting the young and without effective treatment besides radiotherapy. The 2016 World Health Organization (WHO) Central Nervous System (CNS) Tumors Classification defined K27M mutations as pathognomonic but restricted diagnosis to diffuse gliomas involving structures by 2018. Dordaviprone (ONC201) is an oral investigational small molecule, DRD2 antagonist, ClpP...
<p>Volcano plot of differentially expressed genes in DIPG007 cells treated with ONC201 versus vehicle.</p>
<p>Individual cases from historical control datasets.</p>
<p>Expression values, Spearman’s correlation coefficient, and GSEA of genes associated with positive or negative radiographic response to ONC201 treatment.</p>